Search PubMed⌕ Search

PubMed · 15861315

Statins and endothelial dysfunction.

Abstract

The endothelium integrates and modulates critical functions of the arterial wall. As well as regulating vasomotion, it controls inflammation, coagulation, and thrombosis. Many of these actions are mediated through the release of nitric oxide. Endothelial dysfunction is associated with atherosclerosis and its risk factors. It is independently correlated to adverse cardiovascular events, including myocardial infarction, coronary death, and the need for revascularization. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) protect against cardiovascular death, myocardial ischemia, myocardial infarction, and stroke. Although cholesterol reduction accounts for some of these benefits, others appear to be independent of cholesterol lowering. The endothelium mediates many of these "lipid-dependent" and "lipid-independent" actions of statins. This chapter reviews the effects of statins on endothelial dysfunction. To do so, a brief outline of the biology of the endothelium is a prerequisite. This will be followed by a summary of the advances in vascular research on cholesterol-dependent and cholesterol-independent effects of statins, with a focus on the endothelium. Ultimately, clinical relevance of observations derived from basic biology will be discussed.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Eric Larose, Peter Ganz. 2004. Statins and endothelial dysfunction.. https://doi.org/10.1055/s-2004-869590

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The role of statins in reversing atherosclerosis: what the latest regression studies show.

Recent clinical trials confirm that aggressive lipid-lowering therapy with statins decreases low density lipoprotein (LDL) cholesterol to well below 100 mg/dL in high risk patients, and prevents cardiovascular events. Similarly, aggressive lipid lowering is being explored as a possible means of promoting regression of atherosclerosis and of affording greater protection from atherosclerotic events. A growing body of evidence indicates that intensive statin therapy, particularly in high risk patients, slows the rate of progression of atherosclerosis compared with moderate therapy, and that reductions of > or =40% in LDL cholesterol are necessary to achieve atherosclerosis regression. Questions remain regarding the extent of regression achieved with statin therapy and whether to dose statins to achieve a specific LDL-cholesterol level or a certain percent reduction; however, ongoing clinical trials may provide insight and guidance.

Arteriosclerosis↗